Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration

NCT02511613 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Company decision

Conditions

Age-Related Macular Degeneration

Interventions

DRUG: Squalamine Lactate Ophthalmic Solution, 0.2%
DRUG: Placebo Ophthalmic Solution
DRUG: ranibizumab

Sponsor

Ohr Pharmaceutical Inc.